| Identification | Back Directory | [Name]
H-MET-GLU-VAL-GLY-TRP-TYR-ARG-SER-PRO-PHE-SER-ARG-VAL-VAL-HIS-LEU-TYR-ARG-ASN-GLY-LYS-OH | [CAS]
149635-73-4 | [Synonyms]
MK21
MOG (35-55)
MOG (MOUSE, RAT)
MOG (35-55), RAT
MEVGWYRSPFSRVVHLYRNGK
MOG (35-55), MOUSE, RAT
MOG (RAT, MOUSE, 35-55)
MOG (35-55) (rat, Mouse)
H-MEVGWYRSPFSRVVHLYRNGK-OH
MOG PEPTIDE (35-55) (RAT, MOUSE)
MYELIN OLIGODENDROCYTE PROTEIN (35-55)
Myelin Oligodendrocyte Glycoprotein (35-55)
MYELIN OLIGODENDROCYTE GLYCOPROTEIN (35-55), RAT
MYELIN OLIGODENDROCYTE GLYCOPROTEIN (35-55) (MOUSE, RAT)
Myelin Oligodendrocyte Glycoprotien (35-55) rat MOG (35-55)
Myelin Oligodendrocyte Glycoprotein Peptide (35-55), mouse, rat
MYELIN OLIGODENDROCYTE GLYCOPROTEIN PEPTIDE (35-55) (RAT, MOUSE)
MYELIN OLIGODENDROCYTE GLYCOPROTEIN PEPTIDE FRAGMENT 35-55 RAT, MOUSE
MOG(35-55)| Myelin Oligodendrocyte Glycoprotein Peptide: 35-55,rat,mouse
MET-GLU-VAL-GLY-TRP-TYR-ARG-PRO-PRO-PHE-SER-ARG-VAL-VAL-HIS-LEU-TYR-ARG-ASN-GLY-LYS
MET-GLU-VAL-GLY-TRP-TYR-ARG-SER-PRO-PHE-SER-ARG-VAL-VAL-HIS-LEU-TYR-ARG-ASN-GLY-LYS
H-MET-GLU-VAL-GLY-TRP-TYR-ARG-SER-PRO-PHE-SER-ARG-VAL-VAL-HIS-LEU-TYR-ARG-ASN-GLY-LYS-OH
H-MET-GLU-VAL-GLY-TRP-TYR-ARG-SER-PRO-PHE-SER-ARG-VAL-VAL-HIS-LEU-TYR-ARG-ASN-GLY-LYS-OH USP/EP/BP
H-MET-GLU-VAL-GLY-TRP-TYR-ARG-SER-PRO-PHE-SER-ARG-VAL-VAL-HIS-LEU-TYR-ARG-ASN-GLY-LYS-OH (MOUSE, RAT)
MYELIN OLIGODENDROCYTE GLYCOPRTOTEIN PEPTIDE FRAGMENT (33-55) RAT, MOUSE, MOG Peptide (33-55) Rat, Mouse
MET-GLU-VAL-GLY-TRP-TYR-ARG-SER-PRO-PHE-SER-ARG-VAL-VAL-HIS-LEU-TYR-ARG-ASN-GLY-LYS: MEVGWYRSPFSRVVHLYRNGK
L-Lysine, L-methionyl-L-α-glutamyl-L-valylglycyl-L-tryptophyl-L-tyrosyl-L-arginyl-L-seryl-L-prolyl-L-phenylalanyl-L-seryl-L-arginyl-L-valyl-L-valyl-L-histidyl-L-leucyl-L-tyrosyl-L-arginyl-L-asparaginylglycyl- | [EINECS(EC#)]
251-228-4 | [Molecular Formula]
C118H177N35O29S | [MDL Number]
MFCD06796003 | [MOL File]
149635-73-4.mol | [Molecular Weight]
2581.95 |
| Chemical Properties | Back Directory | [density ]
1.48±0.1 g/cm3(Predicted) | [storage temp. ]
-15°C | [solubility ]
≥32.25 mg/mL in H2O; insoluble in EtOH; ≥86 mg/mL in DMSO | [form ]
solid | [color ]
White to off-white | [Water Solubility ]
Soluble to 0.50 mg/ml in water | [Sequence]
H-Met-Glu-Val-Gly-Trp-Tyr-Arg-Ser-Pro-Phe-Ser-Arg-Val-VAL-His-Leu-Tyr-Arg-Asn-Gly-Lys-OH | [InChIKey]
JMTCEFUSRHYJBF-LTFOILMJNA-N |
| Hazard Information | Back Directory | [Description]
MOG (35-55) (149635-73-4) or myelin oligodendrocyte glycoprotein (MOG) 35-55 is a minor component of CNS myelin. MOG (35-55) produces a relapsing-remitting neurological disease with extensive plaque-like demyelination, common to the manifestations of multiple sclerosis. MOG (35-55) induces strong T and B cell responses and is highly encephalitogenic. MOG (35-55) induces T cell-mediated multiple sclerosis in animal models. When co-administered with ITE, MOG (35-55) induces tolerogenic dendritic cells and suppresses disease development in mouse preclinical models of multiple sclerosis.
| [Uses]
Mog (35-55) can be used as an antigen immunized C57BL/6J mice to induces severe chronic experimental autoimmune encephalomyelitis in transgenic mice. | [Biological Activity]
mog (35-55) is a truncated peptide derived from the human myelin oligodendrocyte glycoprotein (mog). mog, a member of the immunoglobulin superfamily, is expressed wildly in the central nervous system. in mouse and rat models for human multiple sclerosis, mog is involved in inducing the experimental autoimmune encephalomyelitis. humoral auto-immunity to the myelin oligodendrocyte glycoprotein (mog) may be associated with the pathogenesis of multiple sclerosis (ms) [1].mog (35-55) is involved in inducing autoantibody production and relapsing-remitting neurological disease causing extensive plaque-like demyelination [2]. in hla-dr2-transgenic mice, myelin oligodendrocyte glycoprotein-35-55 peptide induced severe chronic experimental autoimmune encephalomyelitis [3].mog35-55 was highly encephalitogenic and could induce strong t and b cell responses in rats [4]. in nod/lt mice (h-2g7) and c57bl/6 mice (h-2b), single injection of mog35-55 in cfa could induce ms-like disease [4]. | [storage]
Store at -20°C | [References]
[1]. de march a k, de bouwerie m, kolopp-sarda m n, et al. anti-myelin oligodendrocyte glycoprotein b-cell responses in multiple sclerosis[j]. journal of neuroimmunology, 2003, 135(1): 117-125.
[2]. slavin a, ewing c, liu j, et al. induction of a multiple sclerosis-like disease in mice with an immunodominant epitope of myelin oligodendrocyte glycoprotein[j]. autoimmunity, 1998, 28(2): 109-120.
[3]. rich c, link j m, zamora a, et al. myelin oligodendrocyte glycoprotein‐35–55 peptide induces severe chronic experimental autoimmune encephalomyelitis in hla‐dr2‐transgenic mice[j]. european journal of immunology, 2004, 34(5): 1251-1261.
[4]. slavin a, ewing c, liu j, et al. induction of a multiple sclerosis-like disease in mice with an immunodominant epitope of myelin oligodendrocyte glycoprotein[j]. autoimmunity, 1998, 28(2): 109-120. |
|
|